Cyclin-dependent kinase inhibitor 1A (CDKN1A) mRNA (CDKN1A mRNA)

Cyclin-dependent kinase inhibitor 1A (CDKN1A) mRNA encodes the p21 protein, a critical mediator of cell cycle arrest and a primary transcriptional target of the p53 tumor suppressor [NCBI Gene: 1026]. The p21 protein functions by binding to and inhibiting the activity of cyclin-dependent kinase complexes, such as CDK2 and CDK4/6, which effectively halts the cell cycle at the G1/S transition [UniProt: P38936]. This arrest allows for DNA repair or, if the damage is irreparable, leads to cellular senescence or apoptosis. In many cancers, the loss of CDKN1A expression—often due to p53 mutations—contributes to uncontrolled cell proliferation, making the restoration of CDKN1A mRNA a significant therapeutic goal [PubMed: 21909166]. Current drug development strategies include the use of MDM2 inhibitors like Nutlin-3a to stabilize p53 and increase CDKN1A transcription, as well as experimental mRNA-based therapies designed to directly provide functional CDKN1A transcripts to tumor cells [PubMed: 14707131]. Additionally, p21's role in senescence makes its mRNA a target of interest in anti-aging and anti-fibrotic research.

Other names

p21 mRNACIP1 mRNAWAF1 mRNASDI1 mRNACAP20 mRNAMDA-6 mRNA

Induction of CDKN1A mRNA expression or delivery of exogenous CDKN1A mRNA leads to the production of p21 protein, which inhibits CDK2 and CDK4/6 complexes, resulting in G1 phase cell cycle arrest [UniProt: P38936].